Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* -Patients diagnosed with FD according to the ROME III criteria i) Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to obtaining informed consent ii) Have not received upper endoscopy within the last 6 months prior to enrollment and do not have evidence of structural/organic disease iii) Must have one or more of the following symptoms:~  1. Bothersome postprandial fullness~ 2. Early satiation~ 3. Epigastric pain~ 4. Epigastric burning~* At least one of the FD-related symptoms on the Global Overall Symptom (GOS) scale (bothersome postprandial fullness, early satiation, epigastric pain, epigastric burning) is ≥4, whereas heartburn is ≤3.~* Total score of depression-related symptoms on Hospital Anxiety and Depression Score (HAD) is ≤10.~* Type of visit: Outpatient~* Provides voluntary informed consent after receiving adequate explanation and demonstrates thorough understanding of the nature of the study.~Exclusion Criteria:~* Confirmed ulcer (excluding scars) or malignant tumor in the upper GI~* Suspected organic lesions in the hepato-biliary-pancreatic regions such as cholelithiasis, hepatitis, pancreatitis~* History of upper GI resection~* Serious complications (liver, kidney, heart, or blood disease or metabolic disease)~* Less than a year since testing positive for H. pylori or have undergone a successful eradication therapy~* Use of prohibited medications~* Neuropsychiatric disorders~* Use of or planned use of any investigational drugs~* Unable to take drugs orally~* History of allergic reactions to Kampo medicines~* Pregnant or lactating women or those who are planning to conceive during the study period~* Deemed ineligible by principal investigator or sub-investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rikkunshito Placebo (Type: PLACEBO_COMPARATOR): None
- Rikkunshito (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).